학술논문
FDA pooled analysis of overall survival according to depth of response as a continuous variable in frontline advanced immuno-oncology renal cell carcinoma trials.
Document Type
Article
Author
Source
Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, p418-418, 140p
Subject
Language
ISSN
0732183X